After announcing a major new round of funding, DarioHealth Corp. (Nasdaq: DRIO) announced late last week that the company has initiated a comprehensive strategic review that could transform both the…
Posts published in “Wall Street Wire”
InterCure’s Newly Announced Strategic Acquisition of ISHI Comes at Historic Inflection Point as Trump Administration Explores Cannabis Rescheduling The cannabis industry is buzzing with excitement after President Trump’s drug policy…
TL;DR: The global epinephrine market is set to double to $6-7 billion by 2030, and newly-public Nasus Pharma (NYSE: NSRX) is taking aim at the entire industry with an innovative…
Latest preclinical results validate systemic delivery approach, positioning SIL204 for Phase 2/3 initiation in first half of 2026 Silexion Therapeutics (NASDAQ: SLXN) today announced groundbreaking preclinical data demonstrating that its…
Israeli real estate giant continues operational momentum while executing strategic asset disposal plan G City (TASE: GCT.TA), the global real estate company led by founder and CEO Chaim Katzman, delivered…
Major Israeli TV Channel Feature Highlights Combat-Tested Drone Technologies Behind Israel’s Groundbreaking Military Operations A comprehensive news feature published recently on Israeli television showcased the latest innovative drone technologies being…
Palatin Technologies (OTCQB: PTNT.D) announces game-changing partnership with pharmaceutical giant Boehringer Ingelheim worth potentially hundreds of millions. Here’s why PTNTD could be the breakout story of 2025. David Meets Goliath:…
Second quarter operational discipline and margin expansion demonstrate underlying business strength as company deliberately transitions from one-time contracts to higher-quality recurring revenue streams DarioHealth Corp.’s second quarter 2025 financial results…
The Bottom Line: While trading at a market cap of just around ~$250M, Alpha Tau’s groundbreaking alpha-radiation cancer therapy is showing 90%+ disease control rates and has earned FDA Breakthrough…
Entera Bio’s EB613 could turn a $3,000/month injection into a simple morning pill, and wall street has given it a price target with ~400% upside (NASDAQ: ENTX) The Brief: Entera…